These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
401 related articles for article (PubMed ID: 33583813)
1. An updated perspective and pooled analysis of cardiovascular outcome trials of GLP-1 receptor agonists and SGLT-2 inhibitors. Kılıçkap M; Kayıkçıoğlu M; Tokgözoğlu L Anatol J Cardiol; 2021 Feb; 25(2):61-76. PubMed ID: 33583813 [TBL] [Abstract][Full Text] [Related]
2. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. Palmer SC; Tendal B; Mustafa RA; Vandvik PO; Li S; Hao Q; Tunnicliffe D; Ruospo M; Natale P; Saglimbene V; Nicolucci A; Johnson DW; Tonelli M; Rossi MC; Badve SV; Cho Y; Nadeau-Fredette AC; Burke M; Faruque LI; Lloyd A; Ahmad N; Liu Y; Tiv S; Millard T; Gagliardi L; Kolanu N; Barmanray RD; McMorrow R; Raygoza Cortez AK; White H; Chen X; Zhou X; Liu J; Rodríguez AF; González-Colmenero AD; Wang Y; Li L; Sutanto S; Solis RC; Díaz González-Colmenero F; Rodriguez-Gutierrez R; Walsh M; Guyatt G; Strippoli GFM BMJ; 2021 Jan; 372():m4573. PubMed ID: 33441402 [TBL] [Abstract][Full Text] [Related]
3. Cardiovascular outcomes associated with SGLT-2 inhibitors versus other glucose-lowering drugs in patients with type 2 diabetes: A real-world systematic review and meta-analysis. Li CX; Liang S; Gao L; Liu H PLoS One; 2021; 16(2):e0244689. PubMed ID: 33606705 [TBL] [Abstract][Full Text] [Related]
4. The effect of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors on cardiorenal outcomes: a network meta-analysis of 23 CVOTs. Giugliano D; Longo M; Signoriello S; Maiorino MI; Solerte B; Chiodini P; Esposito K Cardiovasc Diabetol; 2022 Mar; 21(1):42. PubMed ID: 35296336 [TBL] [Abstract][Full Text] [Related]
5. Cardiovascular outcomes with SGLT-2 inhibitors and GLP-1 receptor agonist in Asians with type 2 diabetes: A systematic review and meta-analysis of cardiovascular outcome trials. Singh AK; Singh R Diabetes Metab Syndr; 2020; 14(4):715-722. PubMed ID: 32470852 [TBL] [Abstract][Full Text] [Related]
6. Effects of glucagon-like peptide-1 receptor agonists on major cardiovascular events in patients with Type 2 diabetes mellitus with or without established cardiovascular disease: a meta-analysis of randomized controlled trials. Marsico F; Paolillo S; Gargiulo P; Bruzzese D; Dell'Aversana S; Esposito I; Renga F; Esposito L; Marciano C; Dellegrottaglie S; Iesu I; Perrone Filardi P Eur Heart J; 2020 Sep; 41(35):3346-3358. PubMed ID: 32077924 [TBL] [Abstract][Full Text] [Related]
7. Effectiveness and safety of GLP-1 receptor agonists versus SGLT-2 inhibitors in type 2 diabetes: an Italian cohort study. Baviera M; Foresta A; Colacioppo P; Macaluso G; Roncaglioni MC; Tettamanti M; Fortino I; Genovese S; Caruso I; Giorgino F Cardiovasc Diabetol; 2022 Aug; 21(1):162. PubMed ID: 35999556 [TBL] [Abstract][Full Text] [Related]
8. Cardiovascular outcomes in trials of new antidiabetic drug classes: a network meta-analysis. Fei Y; Tsoi MF; Cheung BMY Cardiovasc Diabetol; 2019 Aug; 18(1):112. PubMed ID: 31462224 [TBL] [Abstract][Full Text] [Related]
9. Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysis. Yamada T; Wakabayashi M; Bhalla A; Chopra N; Miyashita H; Mikami T; Ueyama H; Fujisaki T; Saigusa Y; Yamaji T; Azushima K; Urate S; Suzuki T; Abe E; Wakui H; Tamura K Cardiovasc Diabetol; 2021 Jan; 20(1):14. PubMed ID: 33413348 [TBL] [Abstract][Full Text] [Related]
10. Gender difference in cardiovascular outcomes with SGLT-2 inhibitors and GLP-1 receptor agonist in type 2 diabetes: A systematic review and meta-analysis of cardio-vascular outcome trials. Singh AK; Singh R Diabetes Metab Syndr; 2020; 14(3):181-187. PubMed ID: 32142999 [TBL] [Abstract][Full Text] [Related]
11. Network meta-analysis of nine large cardiovascular outcome trials of new antidiabetic drugs. Alfayez OM; Al Yami MS; Alshibani M; Fallatah SB; Al Khushaym NM; Alsheikh R; Alkhatib N Prim Care Diabetes; 2019 Jun; 13(3):204-211. PubMed ID: 30713085 [TBL] [Abstract][Full Text] [Related]
12. Pharmacologic strategies to reduce cardiovascular disease in type 2 diabetes mellitus: focus on SGLT-2 inhibitors and GLP-1 receptor agonists. Bonaventura A; Carbone S; Dixon DL; Abbate A; Montecucco F J Intern Med; 2019 Jul; 286(1):16-31. PubMed ID: 30888088 [TBL] [Abstract][Full Text] [Related]
13. Comparative efficacy of sodium-glucose co-transporter-2 inhibitors, glucagon-like peptide-1 receptor agonists and non-steroidal mineralocorticoid receptor antagonists in chronic kidney disease and type 2 diabetes: A systematic review and network meta-analysis. Nguyen BN; Nguyen L; Mital S; Bugden S; Nguyen HV Diabetes Obes Metab; 2023 Jun; 25(6):1614-1623. PubMed ID: 36751968 [TBL] [Abstract][Full Text] [Related]
14. The efficacy and safety of novel classes of glucose-lowering drugs for cardiovascular outcomes: a network meta-analysis of randomised clinical trials. Lin DS; Lee JK; Hung CS; Chen WJ Diabetologia; 2021 Dec; 64(12):2676-2686. PubMed ID: 34536085 [TBL] [Abstract][Full Text] [Related]
15. Characteristics predicting the efficacy of SGLT-2 inhibitors versus GLP-1 receptor agonists on major adverse cardiovascular events in type 2 diabetes mellitus: a meta-analysis study. Sohn M; Dietrich JW; Nauck MA; Lim S Cardiovasc Diabetol; 2023 Jun; 22(1):153. PubMed ID: 37381019 [TBL] [Abstract][Full Text] [Related]
16. Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-like Peptide 1 Agonists, and Dipeptidyl Peptidase 4 Inhibitors With All-Cause Mortality in Patients With Type 2 Diabetes: A Systematic Review and Meta-analysis. Zheng SL; Roddick AJ; Aghar-Jaffar R; Shun-Shin MJ; Francis D; Oliver N; Meeran K JAMA; 2018 Apr; 319(15):1580-1591. PubMed ID: 29677303 [TBL] [Abstract][Full Text] [Related]
17. GLP-1 receptor agonists vs. SGLT-2 inhibitors: the gap seems to be leveling off. Giugliano D; Scappaticcio L; Longo M; Bellastella G; Esposito K Cardiovasc Diabetol; 2021 Oct; 20(1):205. PubMed ID: 34641876 [TBL] [Abstract][Full Text] [Related]
18. Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study. Thein D; Christiansen MN; Mogensen UM; Bundgaard JS; Rørth R; Madelaire C; Fosbøl EL; Schou M; Torp-Pedersen C; Gislason G; Køber L; Kristensen SL Cardiovasc Diabetol; 2020 Jul; 19(1):107. PubMed ID: 32631337 [TBL] [Abstract][Full Text] [Related]
19. Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. Shi Q; Nong K; Vandvik PO; Guyatt GH; Schnell O; Rydén L; Marx N; Brosius FC; Mustafa RA; Agarwal A; Zou X; Mao Y; Asadollahifar A; Chowdhury SR; Zhai C; Gupta S; Gao Y; Lima JP; Numata K; Qiao Z; Fan Q; Yang Q; Jin Y; Ge L; Yang Q; Zhu H; Yang F; Chen Z; Lu X; He S; Chen X; Lyu X; An X; Chen Y; Hao Q; Standl E; Siemieniuk R; Agoritsas T; Tian H; Li S BMJ; 2023 Apr; 381():e074068. PubMed ID: 37024129 [TBL] [Abstract][Full Text] [Related]
20. Improvement of glycemic control and reduction of major cardiovascular events in 18 cardiovascular outcome trials: an updated meta-regression. Maiorino MI; Longo M; Scappaticcio L; Bellastella G; Chiodini P; Esposito K; Giugliano D Cardiovasc Diabetol; 2021 Oct; 20(1):210. PubMed ID: 34663316 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]